Načítá se...
(18)F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study
PURPOSE: To determine whether interim 3′-deoxy-3′-[(18)F]fluorothymidine (iFLT) PET/CT is a superior predictor of progression-free survival (PFS) compared with interim (18)F-fluorodeoxyglucose (iFDG) PET/CT in patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab, cyclophosphami...
Uloženo v:
| Vydáno v: | Eur J Nucl Med Mol Imaging |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8263539/ https://ncbi.nlm.nih.gov/pubmed/33909086 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-021-05353-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|